VRCA · Verrica Pharmaceuticals Inc. · Investor Relations
$4.69
-0.11 (-2.29%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$75.07M
Shares
17.18M
Volume · Oct 1
19.21K
Avg daily vol (3M)
62.01K
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-14 | September 14, 2026 | Event |
| 2026-08-19 | August 19, 2026 | Event |
| 2026-08-06 | Q2 FY2026 Earnings conference call (announced in 8-K) | Earnings call |
| 2026-06-04 | Thursday, June 4, 2026 (11:05 am ET) | Webcast |
| 2026-05-19 | Tuesday, May 19, 2026 (1:30pm ET) | Webcast |
| 2026-05-15 | Friday, May 15, 2026 at 4:30 pm – 6:00 pm – Poster Number: LB1190 – VP-315 Demonstrates Potential Abscopal Effect in Untreated Non-Target Basal Cell Carcinoma (BCC) Tumors | Event |
| 2026-05-13 | May 13, 2026 | Event |
| 2026-05-12 | Tuesday, May 12, 2026 (4:30 pm ET) | Event |
| 2026-05-12 | Q1 FY2026 Earnings conference call (announced in 8-K) | Earnings call |
| 2026-03-11 | Earnings conference call (announced in 8-K) | Earnings call |